全文获取类型
收费全文 | 182篇 |
免费 | 0篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 54篇 |
口腔科学 | 1篇 |
临床医学 | 15篇 |
内科学 | 15篇 |
神经病学 | 2篇 |
特种医学 | 4篇 |
外科学 | 8篇 |
预防医学 | 9篇 |
眼科学 | 34篇 |
药学 | 29篇 |
肿瘤学 | 11篇 |
出版年
2022年 | 4篇 |
2021年 | 4篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2016年 | 4篇 |
2013年 | 4篇 |
2012年 | 2篇 |
2011年 | 3篇 |
2010年 | 5篇 |
2009年 | 2篇 |
2008年 | 9篇 |
2007年 | 8篇 |
2006年 | 9篇 |
2005年 | 8篇 |
2004年 | 9篇 |
2003年 | 6篇 |
2002年 | 6篇 |
2001年 | 3篇 |
2000年 | 7篇 |
1999年 | 5篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 12篇 |
1990年 | 2篇 |
1989年 | 7篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1986年 | 2篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1969年 | 2篇 |
1968年 | 1篇 |
1967年 | 3篇 |
1966年 | 1篇 |
1965年 | 2篇 |
1958年 | 1篇 |
排序方式: 共有183条查询结果,搜索用时 31 毫秒
1.
Amosova E. N. Shilova I. V. Zueva E. P. Rybalkina O. Yu. 《Pharmaceutical Chemistry Journal》2020,54(7):721-724
Pharmaceutical Chemistry Journal - Three extracts were produced from the above-ground part of the meadowsweet Filipendula ulmaria (L.) Maxim. using water, 40% ethanol, and 70% ethanol. Comparative... 相似文献
2.
V. E. Kataev O. I. Militsina I. Yu. Strobykina G. I. Kovylyaeva R. Z. Musin O. V. Fedorova G. L. Rusinov M. N. Zueva G. G. Mordovskoi A. G. Tolstikov 《Pharmaceutical Chemistry Journal》2006,40(9):473-475
Diesters based on isosteviol and dicarboxylic acids were synthesized and tested for antituberculous activity. Isosteviol and
some of its derivatives exhibit appreciable tuberculostatic properties in vitro, the activity being dependent on the length of the polymethylene spacer connecting two ent-beyeran fragments. The mechanism of the antituberculous action of isosteviol derivatives are discussed.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 9, pp. 12–13, September, 2006. 相似文献
3.
M. M. Borisov P. P. Doronin L. V. Zueva B. S. Kulaev I. M. Rodionov V. N. Yarygin 《Bulletin of experimental biology and medicine》1975,79(6):619-621
The number of cells in the sympathetic ganglia of rats was reduced by means of guanethidine to 30% (group 1) and to 1% (group 2) of normal. In rats aged 2 months pressor responses to asphyxia and to stimulation of the femoral nerve were absent. In the animals of group 1 (but not of group 2) recovery of the reflexes was observed at the age of 4 months. An increase in the number of neurofibrils was demonstrated in the neurons surviving guanethidine treatment, indicating growth of the axon of these cells. Investigation of responses to the indirect sympathomimetic tyramine revealed an increase in the number of effector sympathetic endings at the periphery at the age of 4 months in the animals of group 1. It is suggested that restoration of reflex responses in the animals of this group at the age of 4 months took place on account of growth and branching of the axons of the surviving nerve cells, as a result of which the density of the effector innervation at the periphery was restored. 相似文献
4.
Zoia R. Korobova Elena V. Zueva Natalia A. Arsentieva Oleg K. Batsunov Natalia E. Liubimova Irina V. Khamitova Raisa N. Kuznetsova Artem A. Rubinstein Tikhon V. Savin Oksana V. Stanevich Alexandr N. Kulikov Dmitry E. Pevtsov Areg A. Totolian 《Viruses》2022,14(5)
IgG is the most prominent marker of post-COVID-19 immunity. Not only does this subtype mark the late stages of infection, but it also stays in the body for a timespan of at least 6 months. However, different IgG subclasses have different properties, and their roles in specific anti-COVID-19 responses have yet to be determined. We assessed the concentrations of IgG1, IgG2, IgG3, and IgG4 against different SARS-CoV-2 antigens (N protein, S protein RBD) using a specifically designed method and samples from 348 COVID-19 patients. We noted a statistically significant association between severity of COVID-19 infection and IgG concentrations (both total and subclasses). When assessing anti-N protein and anti-RBD IgG subclasses, we noted the importance of IgG3 as a subclass. Since it is often associated with early antiviral response, we presumed that the IgG3 subclass is the first high-affinity IgG antibody to be produced during COVID-19 infection. 相似文献
5.
6.
7.
Maria Nadinskaia Marina Maevskaya Vladimir Ivashkin Khava Kodzoeva Irina Pirogova Evgeny Chesnokov Alexander Nersesov Jamilya Kaibullayeva Akzhan Konysbekova Aigul Raissova Feruza Khamrabaeva Elena Zueva 《World journal of gastroenterology : WJG》2021,27(10):959-975
BACKGROUNDAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). Weight loss is a key factor for successful NAFLD and CVD therapy. Ursodeoxycholic acid (UDCA), which is one of the first-line therapeutic agents for treatment of NAFLD, is reported to have a beneficial effect on dyslipidemia and ASCVD risk because of antioxidant properties.AIMTo evaluate the effects of 6 mo of UDCA treatment on hepatic function tests, lipid profile, hepatic steatosis and fibrosis, atherogenesis, and ASCVD risk in men and women with NAFLD, as well as to assess the impact of > 5% weight reduction on these parameters.METHODSAn open-label, multicenter, international noncomparative trial was carried out at primary health care settings and included 174 patients with ultrasound-diagnosed NAFLD who received 15 mg/kg/d UDCA for 6 mo and were prescribed lifestyle modification with diet and exercise. The efficacy criteria were liver enzymes, lipid profile, fatty liver index (FLI), noninvasive liver fibrosis tests (nonalcoholic fatty liver disease fibrosis score and liver fibrosis index), carotid intima-media thickness (CIMT), and ASCVD risk score. To test statistical hypotheses, the Wilcoxon test, paired t-test, Fisher’s exact test, and Pearson''s chi-squared test were used. RESULTSThe alanine aminotransferase (ALT) level changed by -14.1 U/L (-31.0; -5.3) from baseline to 3 mo and by -6.5 U/L (-14.0; 0.1) from 3 to 6 mo. The magnitude of ALT, aspartate transaminase, and glutamyltransferase decrease was greater during the first 3 mo of treatment compared to the subsequent 3 mo (P < 0.001, P < 0.01, P < 0.001, respectively). At 6 mo, in the total sample, we observed a statistically significant decrease in body weight and levels of FLI: 84.9 ± 10.4 vs 72.3 ± 17.6, P < 0.001, total cholesterol: 6.03 ± 1.36 vs 5.76 ± 1.21, Р < 0.001, low-density lipoprotein: 3.86 ± 1.01 vs 3.66 ± 0.91, Р < 0.001, and triglyceride: 3.18 (2.00; 4.29) vs 2.04 (1.40; 3.16), Р < 0.001. No effect on nonalcoholic fatty liver disease fibrosis score or liver fibrosis index was found. The CIMT decreased significantly in the total sample (0.985 ± 0.243 vs 0.968 ± 0.237, P = 0.013), whereas the high-density lipoprotein (Р = 0.036) and 10-year ASCVD risk (Р = 0.003) improved significantly only in women. Fifty-four patients (31%) achieved > 5% weight loss. At the end of the study, the FLI decreased significantly in patients with (88.3 ± 10.2 vs 71.4 ± 19.6, P < 0.001) and without > 5% weight loss (83.5 ± 10.3 vs 72.8 ± 16.7, P < 0.001). The changes in ALT, aspartate transaminase, glutamyltransferase, total cholesterol, and low-density lipoprotein levels were similar between the subgroups.CONCLUSIONUDCA normalizes liver enzymes greatly within the first 3 mo of treatment, improves lipid profile and hepatic steatosis independent of weight loss, and has a positive effect on CIMT in the total sample and 10-year ASCVD risk in women after 6 mo of treatment. 相似文献
8.
Elina Zueva Laila Illán Rubio Frédéric Ducongé Bertrand Tavitian 《International journal of cancer. Journal international du cancer》2011,128(4):797-804
Metastasis, the capacity of tumour cells to disseminate and grow at distant sites, is the main factor in cancer mortality. Compounds inhibiting migration and invasion of cancer cells are promising candidates for anticancer therapy strategies. We have generated nuclease‐resistant RNA ligands (aptamers) recognizing highly metastatic cells with high affinity and specificity, and inhibiting their migratory and invasive potentials. Aptamers were generated by a cell‐based subtractive SELEX technology using isogenic cell lines with similar tumorigenic potentials but opposite metastatic aggressiveness. Two aptamers, E37 and E10, bound specifically to the metastatically aggressive cell line and altered the phosphorylation of several tyrosine kinases. Fluorescent microscopy showed intracellular uptake of E37, in contrast to membrane binding of E10. Both aptamers inhibited migration of tumour cells in culture (50 and 85% inhibition with respect to control pool for E10 and E37, respectively) while only E10 inhibited cell invasion (?75% with respect to control pool). This proof‐of‐concept study demonstrates the potential of cell‐based SELEX to yield ligands that selectively recognize aggressive metastatic cells and inhibit phenotypes linked to metastatic potential. 相似文献
9.
10.